Seagen and Genmab file 'trojan horse' drug with FDA for cerv...

Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer.

Genmab axes development of AXL-targeting cancer drug enapota...

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial.

AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

J&J defends Darzalex with FDA approval for faster dosing

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.